| Ytd | -12.33% | |
| 1y | 4.07% |
| Open | 6.97 | Prev Close | 6.91 | Low | 6.82 | High | 7.25 | Mkt Cap | 252.07M |
| Vol | 428.72K | Avg Vol | 168.28K | EPS | -0.99 | P/E | N/A | Forward P/E | -7.95 |
| Beta | 0.83 | Short Ratio | 7.87 | Inst. Own | 35.99% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 6.59 | 200-d Avg | 6.81 | 1yr Est | 15.30 |
PROF News
Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher th
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a comme
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Teli
Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's
Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers
Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market sessio
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a comme
Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus
TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a comme
TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound
Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA
TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”
A patient-centered initiative focused on education, connection, and support A patient-centered initi
Profound Medical NASDAQ: PROF reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from C
Profound Medical (PROF) came out with quarterly earnings of $0.26 per share, beating the Zacks Conse
Profound Medical (NASDAQ:PROF) affirms FY2026 sales outlook from $25.000 million to $25.000 million
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which met the analyst
– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1
– Whole-gland TULSA ablation demonstrates statistically significant superior penile length preservat
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”
TORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume
The average of price targets set by Wall Street analysts indicates a potential upside of 59.7% in Pr
Telix to partner with companies developing advanced minimally invasive and image-guided ablative tec
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF)
Profound Medical NASDAQ: PROF reported sharply higher first-quarter revenue and reiterated its view
Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript
Profound Medical (TSX:PRN) reported quarterly losses of $(0.19) per share which beat the analyst con
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a comme
Opportunity to buy undervalued health care stocks. RSI is a momentum indicator that compares strengt
– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP f
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.27) per share which missed the analy
Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexua
Lake Street analyst Benjamin Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and raise
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a comme
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today an
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a comme
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which beat the analyst
Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company&
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a comme
Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company&
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a comme
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.52) per share which missed the analy